<p><strong>Patients with renal impairment</strong>: The use of Zoledronic Acid in patients with creatinine clearance &lt;35 mL/min is not recommended due to limited clinical safety data in such patients. No dose adjustment is necessary in patients with creatinine clearance &gt;35 mL/min.<br />
<br />
<strong>Patients with hepatic impairment</strong>: No dose adjustment is required for patients with hepatic impairment.<br />
<br />
<strong>Elderly patients</strong>: No dose adjustment is required. However, because decreased renal function occurs more commonly in the elderly, special care should be taken to monitor renal function.<br />
<br />
Zoledronic Acid must not be mixed or given intravenously with any other medication and must be given through a separate infusion line at a constant infusion rate. If refrigerated, allow the refrigerated solution to reach room temperature before administration. Aseptic techniques must be followed during the preparation of the infusion. Any unused solution should be discarded. Only clear solution free from particles and discoloration should be used.<br />
<br />
After opening, the solution is chemically and physically stable for at least 24 hours at 2&deg;C to 8&deg;C. From a microbiological point of view, the product should be used immediately. Zoledronic Acid solution for infusion must not be allowed to come into contact with any Calcium or other divalent cation-containing solutions.</p>